Reuters: Regulatory News: U.S. FDA panel backs Paladin Labs' parasitic disease drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Thousands of Free eBooks BookBub brings you free & bargain national bestselling eBooks in the genres of your choice! Sign up now & join 1.5 million happy readers. From our sponsors

U.S. FDA panel backs Paladin Labs' parasitic disease drug Oct 18th 2013, 18:49 Fri Oct 18, 2013 2:49pm EDT Oct 18 (Reuters) - Paladin Labs Inc's experimental drug to treat a rare parasitic disease is safe and effective enough to be approved, an advisory panel to the U.S. Food and Drug Administration said on Friday. The drug, Impavido, is designed to treat three forms of leishmaniasis, a disease caused by a group of parasites known as Leishmania, which are spread by the bite of a female sand-fly. The FDA is not bound to follow its advisory panel's advice but typically does so.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions